<qa>  How many subjects were enrolled in this study?A total of 40 subjects were enrolled in this study, in 5 cohorts of 8 subjects each. Six of the 8 subjects in each cohort received study drug and 2 subjects received placebo 0.9 sodium chloride, saline. The first cohort was dosed with 10 mg. Succeeding cohorts received 30 mg, 60 mg, 120 mg, and 240 mg of CD24Fc or matching placebo and were dosed at least 3 weeks apart to allow for review of safety and tolerability data for each prior cohort. Administration of the next higher dose to a new cohort of subjects was permitted only if adequate safety and tolerability had been demonstrated. 